Header Logo

Connection

KENNETH MCCLAIN to Histiocytosis, Langerhans-Cell

Back to Details
This is a "connection" page, showing publications KENNETH MCCLAIN has written about Histiocytosis, Langerhans-Cell.
KENNETH MCCLAIN
Connection Strength
13.967
Histiocytosis, Langerhans-Cell
  1. Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine. Pediatr Hematol Oncol. 2023; 40(5):497-505.
    View in: PubMed
    Score: 0.631
  2. BRAF V600E vs cell of origin: what governs LCH? Blood. 2021 10 07; 138(14):1203-1204.
    View in: PubMed
    Score: 0.578
  3. Histiocytic disorders. Nat Rev Dis Primers. 2021 10 07; 7(1):73.
    View in: PubMed
    Score: 0.578
  4. Histiocytic Diseases of Neonates: Langerhans Cell Histiocytosis, Rosai-Dorfman Disease, and Juvenile Xanthogranuloma. Clin Perinatol. 2021 03; 48(1):167-179.
    View in: PubMed
    Score: 0.549
  5. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):395-399.
    View in: PubMed
    Score: 0.545
  6. Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Pediatr Hematol Oncol. 2018 Oct - Nov; 35(7-8):427-433.
    View in: PubMed
    Score: 0.477
  7. Anti TNF-a therapy in patients with relapsed and refractory Langerhans cell histiocytosis: a phase II study. Pediatr Hematol Oncol. 2018 Aug - Sep; 35(5-6):362-368.
    View in: PubMed
    Score: 0.474
  8. Langerhans-Cell Histiocytosis. N Engl J Med. 2018 08 30; 379(9):856-868.
    View in: PubMed
    Score: 0.466
  9. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.453
  10. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
    View in: PubMed
    Score: 0.408
  11. How I treat Langerhans cell histiocytosis. Blood. 2015 Jul 02; 126(1):26-35.
    View in: PubMed
    Score: 0.368
  12. Treatment of Langerhans cell histiocytosis: it is time to learn from the past: response to Minkov and Rodriguez-Galindo. Br J Haematol. 2015 Oct; 171(1):150-1.
    View in: PubMed
    Score: 0.368
  13. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013 May 14; 8:72.
    View in: PubMed
    Score: 0.323
  14. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012; 7(8):e43257.
    View in: PubMed
    Score: 0.307
  15. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010 Apr 15; 184(8):4557-67.
    View in: PubMed
    Score: 0.259
  16. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010 Mar; 54(3):416-23.
    View in: PubMed
    Score: 0.259
  17. Interleukin-17A is not expressed by CD207(+) cells in Langerhans cell histiocytosis lesions. Nat Med. 2009 May; 15(5):483-4; author reply 484-5.
    View in: PubMed
    Score: 0.244
  18. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
    View in: PubMed
    Score: 0.240
  19. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan; 52(1):97-101.
    View in: PubMed
    Score: 0.239
  20. EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH. Pediatr Blood Cancer. 2008 Mar; 50(3):728-30.
    View in: PubMed
    Score: 0.225
  21. Langerhans cell histiocytosis: a review of past, current and future therapies. Drugs Today (Barc). 2007 Sep; 43(9):627-43.
    View in: PubMed
    Score: 0.217
  22. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan; 48(1):44-9.
    View in: PubMed
    Score: 0.208
  23. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother. 2005 Nov; 6(14):2435-41.
    View in: PubMed
    Score: 0.192
  24. BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood. 2025 Jul 10; 146(2):206-218.
    View in: PubMed
    Score: 0.187
  25. Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder. J Clin Endocrinol Metab. 2025 May 19; 110(6):1756-1766.
    View in: PubMed
    Score: 0.186
  26. Expression profiling using human tissues in combination with RNA amplification and microarray analysis: assessment of Langerhans cell histiocytosis. Amino Acids. 2005 May; 28(3):279-90.
    View in: PubMed
    Score: 0.184
  27. Mixed histiocytic disorders: Nature versus nurture? Br J Haematol. 2024 Jul; 205(1):20-21.
    View in: PubMed
    Score: 0.173
  28. Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures. Cancer. 2024 Jul 15; 130(14):2416-2439.
    View in: PubMed
    Score: 0.173
  29. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
    View in: PubMed
    Score: 0.171
  30. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1882-1887.
    View in: PubMed
    Score: 0.171
  31. Atypical cellular disorders. Hematology Am Soc Hematol Educ Program. 2004; 283-96.
    View in: PubMed
    Score: 0.169
  32. Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders. Immunity. 2023 12 12; 56(12):2790-2802.e6.
    View in: PubMed
    Score: 0.168
  33. Langerhans cell histiocytosis patients have HLA Cw7 and DR4 types associated with specific clinical presentations and no increased frequency in polymorphisms of the tumor necrosis factor alpha promoter. Med Pediatr Oncol. 2003 Dec; 41(6):502-7.
    View in: PubMed
    Score: 0.168
  34. Need for a cooperative study: Pulmonary Langerhans cell histiocytosis and its management in adults. Med Pediatr Oncol. 2002 Jul; 39(1):35-9.
    View in: PubMed
    Score: 0.152
  35. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 04 28; 139(17):2601-2621.
    View in: PubMed
    Score: 0.150
  36. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nat Med. 2021 05; 27(5):851-861.
    View in: PubMed
    Score: 0.140
  37. Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood. 2021 04 01; 137(13):1777-1791.
    View in: PubMed
    Score: 0.139
  38. Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Adv. 2020 01 14; 4(1):87-99.
    View in: PubMed
    Score: 0.128
  39. BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor. Blood Adv. 2019 06 25; 3(12):1848-1853.
    View in: PubMed
    Score: 0.123
  40. The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann Epidemiol. 2018 08; 28(8):521-528.
    View in: PubMed
    Score: 0.114
  41. An update on clonality, cytokines, and viral etiology in Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr; 12(2):407-16.
    View in: PubMed
    Score: 0.113
  42. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med. 2018 01 02; 215(1):319-336.
    View in: PubMed
    Score: 0.111
  43. DNA polymorphisms and mutations of the tumor necrosis factor-alpha (TNF-alpha) promoter in Langerhans cell histiocytosis (LCH). J Interferon Cytokine Res. 1997 Oct; 17(10):631-5.
    View in: PubMed
    Score: 0.109
  44. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer. 2018 Jan; 65(1).
    View in: PubMed
    Score: 0.109
  45. A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood. 2017 11 16; 130(20):2229-2232.
    View in: PubMed
    Score: 0.109
  46. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 07 13; 130(2):167-175.
    View in: PubMed
    Score: 0.107
  47. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018 Feb; 36(1):307-315.
    View in: PubMed
    Score: 0.105
  48. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.103
  49. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
    View in: PubMed
    Score: 0.102
  50. Cell(s) of Origin of Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2015 Oct; 29(5):825-38.
    View in: PubMed
    Score: 0.094
  51. Recognition and treatment of concurrent active and neurodegenerative langerhans cell histiocytosis: a case report. J Pediatr Hematol Oncol. 2015 Jan; 37(1):e37-40.
    View in: PubMed
    Score: 0.090
  52. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood. Br J Haematol. 2015 Apr; 169(2):241-8.
    View in: PubMed
    Score: 0.090
  53. Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone? Br J Haematol. 2015 Apr; 169(2):299-301.
    View in: PubMed
    Score: 0.090
  54. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014 Nov; 165(5):990-6.
    View in: PubMed
    Score: 0.089
  55. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014 Nov 06; 124(19):3007-15.
    View in: PubMed
    Score: 0.088
  56. Langerhans cell histiocytosis: lack of a viral etiology. Am J Hematol. 1994 Sep; 47(1):16-20.
    View in: PubMed
    Score: 0.088
  57. Viruses and Langerhans cell histiocytosis: is there a link? Br J Cancer Suppl. 1994 Sep; 23:S34-6.
    View in: PubMed
    Score: 0.088
  58. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 07; 211(4):669-83.
    View in: PubMed
    Score: 0.086
  59. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014 Mar; 61(3):479-87.
    View in: PubMed
    Score: 0.083
  60. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20; 121(25):5006-14.
    View in: PubMed
    Score: 0.080
  61. Neither IL-17A mRNA nor IL-17A protein are detectable in Langerhans cell histiocytosis lesions. Mol Ther. 2011 Aug; 19(8):1433-9.
    View in: PubMed
    Score: 0.071
  62. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010 Jun; 156(6):873-881.e1.
    View in: PubMed
    Score: 0.066
  63. Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated? Pediatr Blood Cancer. 2009 May; 52(5):555-6.
    View in: PubMed
    Score: 0.061
  64. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr. 2008 Nov; 153(5):700-5, 705.e1-2.
    View in: PubMed
    Score: 0.058
  65. In vivo transformation of mouse conventional CD8alpha+ dendritic cells leads to progressive multisystem histiocytosis. Blood. 2008 Feb 15; 111(4):2073-82.
    View in: PubMed
    Score: 0.055
  66. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005 Mar; 44(3):251-4.
    View in: PubMed
    Score: 0.046
  67. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol. 2005 Mar 01; 174(5):3067-71.
    View in: PubMed
    Score: 0.046
  68. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Jul; 43(1):81-4.
    View in: PubMed
    Score: 0.044
  69. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004 May; 42(5):438-44.
    View in: PubMed
    Score: 0.043
  70. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003 Nov; 39(16):2341-8.
    View in: PubMed
    Score: 0.042
  71. Bone marrow involvement in histiocytosis X. Med Pediatr Oncol. 1983; 11(3):167-71.
    View in: PubMed
    Score: 0.039
  72. Adult Langerhans cell histiocytosis limited to the skin. Dermatology. 2003; 207(2):157-61.
    View in: PubMed
    Score: 0.039
  73. Evaluation of human herpesvirus type 8 infection in childhood langerhans cell histiocytosis. Am J Hematol. 2000 Aug; 64(4):237-41.
    View in: PubMed
    Score: 0.033
  74. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 05 28; 135(22):1929-1945.
    View in: PubMed
    Score: 0.033
  75. Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med. 1994 Jul 21; 331(3):154-60.
    View in: PubMed
    Score: 0.022
  76. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S82-9.
    View in: PubMed
    Score: 0.016
  77. Acquired immune deficiency, myelodysplasia, and acute nonlymphocytic leukemia associated with monosomy 7 and t(3;3) (q21;q26) in a child with Langerhans cell histiocytosis. Am J Pediatr Hematol Oncol. 1989; 11(2):153-7.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.